Functional characterization of platelet ADP receptors

Platelets

Volumn 9, Issue 6, 1998, Pages 343-351

  Kunapuli, S P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; PURINE P2 RECEPTOR; THROMBOCYTE RECEPTOR;

HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 0031786662     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109876401     Document Type: Review

References (107)

1. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 1994; 72: 278-84.
2. Hourani SMO, Cusack NJ. Pharmacological receptors on blood platelets. Pharmacol Rev 1991; 43: 243-98.
3. Gaarder A, Jonsen A, Laland S, Hellem AJ, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature (Lond) 1961; 192: 531-2.
4. Mills DCB, Robb IA, Roberts GCK. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J Physiol 1968; 195: 715-29.
5. Holmsen H, Weiss HJ. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 1970; 19: 643-9.
6. Holmsen H, Weiss HJ. Secretable storage pools in platelets. Ann Rev Med 1979; 30: 119-34.
7. Burnstock G. A basis for distinguishing two types of purinergic receptors. In: (RW Straub, L Bolis) eds. Membrane Receptors for Drugs and Hormones A Multidisciplinary Approach New York: Raven Press, 1978; 107-18.
8. Dubyak GR, el-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265: C577-606.
9. Fredholm B, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994; 46: 143-56.
10. Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 1997; 18: 79-82.
11. North RA, Barnard EA. Nucleotide receptors. Curr Opin Neurobiol 1997; 7: 346-57.
12. Communi D, Govaerts C, Parmentier M, et al. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 1997; 272: 31969-73.
13. Akbar GKM, Dasari VR, Webb TE, et al. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem 1996; 271: 18363-7.
14. Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620-24.
15. Pianet I, Merle M, Labouesse J. ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoprotrenol-stimulated C6 glioma cells. Biochem Biophys Res Comm 1989; 1163: 1150-7.
16. Barnard EA, Burnstock G, Webb TA. G protein-coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol Sci 1994; 15: 67-70.
17. Boyer JL, Lazarowski ER, Chen X-H, et al. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J Pharmacol Exp Ther 1993; 267: 1140-6.
18. Cooper DMF, Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979; 282: 517-8.
19. Hourani SMO, Hall DA. Receptors for ADP on human platelets. Trends Pharmacol Sci 1994; 15: 103-8.
20. Born GVR. Platelet aggregation and its reversal. Nature 1962; 194: 927-9.
21. Daniel JL, Molish IR, Holmsen H. Myosin phosphorylation in intact platelets. J Biol Chem 1981; 256: 7510-4.
22. Macfarlane DE. Agonists and receptors: adenosine diphosphate. In (H. Holmsen) eds Platelet Responses and Metabolism, Vol II: Receptors and Metabolism. Boca Raton FL. CRC Press, 1987; 19-36.
23. Mustard JF, Perry DW, Kinlough-Rathbone RL, et al. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1857-65.
24. Macfarlane DE, Gardner S, Lipson C, et al. Malondialdehyde production by platelets during secondary aggregation. Thromb Haemost 1977; 38: 1002-9.
25. +2 in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989; 62: 968-976.
26. Pengo V, Boschello A, Marzari A, et al. Adenosine diphosphate (ADP)-induced α-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost 1986; 56: 147-50.
27. Rinder CS, Student LA, Bonan JL, et al. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 1993; 82: 505-12.
28. Mills DCB. ADP receptor in platelets. Thromb Haemost 1996; 76: 835-56.
29. Rand ML, Perry DW, Packham MA, et al. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of β-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 1996; 52: 288-94.
30. Kaplan KL, Broekman MJ, Chernoff A, et al. Platelet α-granule proteins: studies on release and subcellular localization. Blood 1979; 53: 604-18.
31. Gachet C, Hechler B, Leon C, et al. Activation of ADP receptors and platelet function. Thromb Haemost 1997; 77: 271-5.
32. i2 proteins. Biochem J 1995; 312: 775-9.
33. Sage SO, Rink T. Kinetic differences between thrombin-induced and ADP-induced calcium influx and release from internal stores in fura-2-loaded human platelets. Biochem Biophys Res Commun 1986; 136: 1124-9.
34. 2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-81.
35. Hallam TJ, Rink TJ. Response to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator Quin 2. J Physiol 1985; 368: 131-46.
36. 3 formation in human platelets. FEBS Lett 1986; 206: 299-303
37. Olbrich C, Aepfelbacher M, Siess W. Epinephrine potentiates calcium mobilization and activation of protein kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. Cell Signal 1989; 1: 483-92.
38. +2 ATPase in calcium responses of single, fibrinogen-bound platelets. J Biol Chem 1993; 268: 356-63.
39. Raha S, Jones GD, Gear ARL. Sub-second oscillations of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate during platelets activation by ADP and thrombin: lack of correlation with calcium kinetics. Biochem J 1993; 292: 643-6.
40. Vickers JD, Kinlough-Rathbone RL, Packham MA, et al. Inositol phospholipid metabolism in human platelets stimulated by ADP. Eur J Biochem 1990; 193: 521-8.
41. Vickers JD. ADP-stimulated fibrinogen binding is necessary for some of the inositol phospholipid changes found in ADP-stimulated platelets. Eur J Biochem 1993; 216: 231-7.
42. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. I: evidence for three distinct ADP receptors on platelets. J Biol Chem 1998; 273: 2024-9.
43. Humphries RG, Tomlinson W, Ingall AH, et al. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994; 113: 1057-63.
44. 2T-purinergic receptor antagonist. FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol 1995; 115: 1110-6.
45. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-81.
46. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98.
47. 1. Biochem Pharmacol 1990; 40: 2683-7.
48. Gachet C, Stierle A, Cazenave J-P, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990; 40: 229-38.
49. Mills DCB, Puri RN, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Atheroscler Thromb 1992; 12: 430-6.
50. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
51. Greco NJ, Yamamoto N, Jackson BW, et al. Identification of a nucleotide-binding site on glycoprotein IIb. Relationship to platelet activation. J Biol Chem 1991; 266: 13627-33.
52. Agarwal AK, Tandon NN, Greco NJ, et al. Evaluation of the binding to fixed platelets of agonists and antagonists of ADP-induced platelet aggregation. Thromb Haemost 1989; 62: 1103-6.
53. Greco NJ, Tandon NN, Jackson BW, et al. Low structural specificity for nucleoside triphosphates as antagonists of ADP-induced platelet activation. J Biol Chem 1992; 267: 2966-70.
54. Greco NJ, Tandon NN, Jackson B, et al. Adenine nucleotide binding and photoincorporation in Glanzmann's thrombasthenic platelets. Biochim Biophys Acta 1995; 1236: 142-8.
55. Mills DCB. Factors influencing the adenylate cyclase system in blood platelets. In: (S. Sherry, A. Scriabine) eds Platelets and Thrombosis Baltimore: University Park Press, 1974; 45-67.
56. 2+ influx into stimulated platelets. Blood 1985; 66: 731-4.
57. 32P]ATP. Biochim Biophys Acta 1992; 1137: 77-81.
58. Bennett JS, Colman RF, Colman RW. Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labelling with 5-p-fluorosulfonylbenzoyl adenosine. J Biol Chem 1978; 253: 7346-54.
59. Figures WR, Scearce L, Wachtfogel Y, et al. Platelet ADP receptor and α2-adrenoceptor interaction. Evidence for an ADP requirement for epinephrine-induced platelet activation and an influence of epinephrine on ADP binding. J Biol Chem 1986; 261: 5981-6.
60. Colman RW. Aggregin: a platelet ADP receptor that mediates aggregation. FASEB J 1990; 3: 1425-35.
61. Mills DCB, Figures WR, Scearce LM, et al. Two mechanisms for inhibition of ADP-induced platelet shape change by 5′-p-fluorosulfonylbenzoyl adenosine: conversion to adenosine and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase. J Biol Chem 1985; 260: 8078-83.
62. Rao AK, Kowalska MA. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5′-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist. Blood 1987; 70: 751-6.
63. Puri RN, Kumar A, Chen H, et al. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP. J Biol Chem 1995; 270: 24482-8.
64. Puri RN, Colman RF, Colman RW. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio) adenosine 5′diphosphate is mediated by its binding to a putative ADP receptor, aggregin. Eur J Biochem 1996; 236: 862-70.
65. Puri RN, Colman RW. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1, 3-diazole: Covalent modification of aggregin, a putative ADP receptor. J Cell Biochem 1996; 61: 97-108.
66. Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997; 3: 437-502.
67. 32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 1982; 21: 544-9.
68. 32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983; 71: 420-8.
69. Salzman EW. Cyclic AMP in platelet function. New Engl J Med 1972; 286: 358-63.
70. Haslam RJ, Davidson MML, Desjardins JV. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J 1978; 176: 83-95.
71. Macfarlane DE, Mills DCB. The effects of ATP on platelets: Evidence against the central role of ADP in primary aggregation. Blood 1975; 46: 309-20.
72. Cusack NJ, Hourani SMO. Adenosine diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of adenylate cyclase are mediated by different receptors. Br J Pharmacol 1982; 76: 221-7.
73. 1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-90.
74. Cattaneo M, Lecchi A, Randi AM, et al. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5′-diphosphate. Blood 1992; 80: 2787-96.
75. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995; 95: 1612-22.
76. Savi P, Artcanuthurry V, Bornia J, et al. Effect of clopidogrel treatment on ADP-induced phosphorylations in rat platelets. Br J Haematol 1997; 97: 185-91.
77. Gachet C, Savi P, Ohlmann P, et al. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes - an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost 1992; 68: 79-83.
78. Savi P, Laplace MC, Herbert J-M. Evidence for the existance of two different ADP-binding sites on rat platelets. Thromb Res 1994; 76: 157-69.
79. Gachet C, Cattaneo M, Ohlmann P, et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-44.
80. Vial C, Hechler B, Leon C, et al. Presence of P2X(1) purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-4.
81. Leon C, Hechler B, Vial C, et al. The P2y(1) Receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30.
82. Offermanns S, Toombs CF, Hu Y-H, et al. Defective platelet activation in Gαq-deficient mice. Nature 1997; 389: 183-6.
83. May JA, Heptinstall S, Spangenberg P. Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096. Blood Coag Fibrinoly 1996; 7: 221-4.
84. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II: The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-34.
85. Boyer JL, Romeroavila T, Schachter JB, et al. Identification of competitive antagonists of the P2Y(1) receptor. Mol Pharmacol 1996; 50: 1323-9.
86. 2x receptor for extracellular ATP. Nature 1994; 371: 516-9.
87. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44; 527-32.
88. Vittet D, Mathieu MN, Launay JM, et al. Platelet receptor expression on three human megakaryoblast-like cell lines. Exp Hematol 1997; 20: 1129-34.
89. Cristalli G, Mills DCB. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J 1993; 291: 875-81.
90. Boarder MR, Weisman GA, Turner JT, et al. G protein-coupled P2 purinoceptors: from molecular biology to functional responses. Trends Pharmacol Sci 1995; 16: 133-9.
91. Ayyanathan K, Webb TE, Sandhu AK, et al. Cloning and chromosomal localization of human P2Y1 purinoceptor. Biochem Biophys Res Commun 1996; 218: 783-8.
92. Leon C, Vial C, Cazenave JP, et al. Cloning and sequencing of a human cDNA encoding endothelial P2y(1) purinoceptor. Gene 1996; 171: 295-7.
93. Ayyanathan K, Naylor SL, Kunapuli SP. Structural characterization and fine chromosomal mapping of the human P2Y1 purinergic receptor gene (P2YR1). Som Cell Mol Genet 1996; 22: 419-24.
94. Schachter JB, Li Q, Boyer JL, et al. Second messenger cascade specificity and pharmacological selectivity of the human P2yl-purinoceptor. Br J Pharmacol 1996; 118: 167-73.
95. Webb TE, Simon J, Krishek BJ, et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett 1993; 324: 219-25.
96. Barnard EA, Simon J, Webb TE. Nucleotide receptors in the nervous system - an abundant component using diverse transduction mechanisms [Review], Mol Neurobiol 1997; 15: 103-29.
97. 2 purinergic receptors on human erythroleukemia cells. J Recep Signal Transd Res 1996; 16: 209-24.
98. Lustig KD, Shiau AK, Brake AJ, et al. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc Natl Acad Sci USA 1993; 90: 5113-7.
99. Lanza F, Stierle A, Gachet C, et al. Differential effects of extra-and intracellular calcium chelation on human platelet function and glycoprotein IIb-IIIa complex stability. Nouvelle Revue Francaise d'Hematologie 1992; 34: 123-31.
100. Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adenaline through α2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost 1993; 70: 506-13.
101. Jin J, Kunapuli SP. Co-activation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Nat Acad Sci USA 1998; 95: 8070-8074.
102. Savi P, Beauverger P, Labouret C, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
103. Gabbeta J, Yang X, Kowalska MA, et al. Platelet signal transduction defect with Ga subunit disfunction and diminished Gaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997; 94: 8750-5.
104. Hung DT, Wong YH, Vu TKH, et al. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 1992; 267: 20831-4.
105. Siess W. Multiple signal-transduction pathways synergize in platelet activation. News Physiol Sci 1991; 6: 51-6.
106. 2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-7.
107. 2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949-56.